3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
3
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
4
Rectal Neoplasms
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Radiosurgery
7
Oxaliplatin
7
Docetaxel
7
Paclitaxel
5
Fluorouracil
5
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Carboplatin
4
Capecitabine
4
Trastuzumab
3
Radiotherapy
3
Radiation
3
Leucovorin
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
Cetuximab
3
Bevacizumab
3
spartalizumab
2
sipuleucel-T
2
repotrectinib
2
pembrolizumab
2
pazopanib
2
orteronel
2
fludarabine
2
atezolizumab
2
aldesleukin
2
Temozolomide
2
Surveys and Questionnaires
2
Sunitinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasm Metastasis
×
tucatinib
×
Clear all
NCT04896320
2023-06-22
2019-101826
Providence Health & Services
Phase 1/2
Withdrawn